Medicina clinica · 2009
[Prevalence of use of hormone replacement therapy in women participating in a breast cancer screening program].
Сравнительное исследованиеАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martínez-Pino Isabel, Puig Teresa, Quintana María Jesús, Solà Judit, Bonfill Xavier
Аннотация
BACKGROUND AND OBJECTIVE: The purpose of the study was to determine the prevalence and type of hormone replacement therapy (HRT) in participants in a breast cancer screening program (BCSP) in Barcelona.
PATIENTS AND METHOD: Prevalence of use of HRT was obtained through a survey. Information about type of HRT, gynecological history and socioeconomic and educational level was collected. Prevalence was calculated with its corresponding 95% confidence interval.
RESULTS: From May 2001 to June 2005 there were 21835 participants in the BCSP with a mean age of 57,6 years. Most of the participants were postmenopausal (86,7%). Confirmed prevalence of use of HRT was 5,2%(CI95% 5,3-6,0) with a greater use among women aged 55 to 59 years. The most frequent types of HRT were tibolone (39,5%) followed by combined estrogens plus progestin (30,4%). Higher education was associated with a higher use of HRT. Neither the use or the type of HRT influenced the results of the screening program.
CONCLUSIONS: Prevalence of use of HRT was 5,2% in this study. The most frequently used agents were tibolone and combined estrogens plus progestin.
PATIENTS AND METHOD: Prevalence of use of HRT was obtained through a survey. Information about type of HRT, gynecological history and socioeconomic and educational level was collected. Prevalence was calculated with its corresponding 95% confidence interval.
RESULTS: From May 2001 to June 2005 there were 21835 participants in the BCSP with a mean age of 57,6 years. Most of the participants were postmenopausal (86,7%). Confirmed prevalence of use of HRT was 5,2%(CI95% 5,3-6,0) with a greater use among women aged 55 to 59 years. The most frequent types of HRT were tibolone (39,5%) followed by combined estrogens plus progestin (30,4%). Higher education was associated with a higher use of HRT. Neither the use or the type of HRT influenced the results of the screening program.
CONCLUSIONS: Prevalence of use of HRT was 5,2% in this study. The most frequently used agents were tibolone and combined estrogens plus progestin.
Предметные рубрики MeSH
AgedAntineoplastic Agents, HormonalBreast NeoplasmsConfidence IntervalsData Interpretation, StatisticalEstrogen Replacement TherapyEstrogensFemaleHealth SurveysHormone Replacement TherapyHumansMass ScreeningMenopauseMiddle AgedNorpregnenesPostmenopausePrevalenceProgestinsSocioeconomic FactorsSpainSurveys and Questionnaires